Discover
RNAC
Cartesian Therapeutics, Inc.
10.18
2 x 7.49
2 x 13.14
bid
ask
-
0.24
2.30%
2 @ 04:00 PM
10.00 -0.18 (1.77%)
| Ytd | 41.19% | |
| 1y | -6.52% |
10.10
day range
10.62
5.60
52 week range
15.57
| Open | 10.40 | Prev Close | 10.42 | Low | 10.10 | High | 10.62 | Mkt Cap | 299.10M |
| Vol | 151.65K | Avg Vol | 288.13K | EPS | -5.80 | P/E | N/A | Forward P/E | -5.54 |
| Beta | N/A | Short Ratio | 15.83 | Inst. Own | 27.85% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-30 | 50-d Avg | 7.75 | 200-d Avg | 7.69 | 1yr Est | 38.17 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-07 | 2024-09 | -0.78 | -0.69 | 0.09 | 11.54% |
| 2024-08-08 | 2024-06 | -0.81 | 0.54 | 1.35 | 166.67% |
| 2024-05-08 | 2024-03 | -0.81 | -1.97 | -1.16 | -143.21% |
| 2024-03-07 | 2023-12 | -0.3 | -2.4 | -2.1 | -700.00% |
| 2023-11-13 | 2023-09 | -2.1 | -2.4 | -0.3 | -14.29% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-19 | BTIG | Upgrade | Buy | |
| 2024-12-04 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-12-03 | Needham | Upgrade | Buy | Buy |
| 2024-11-25 | Needham | Upgrade | Buy | Buy |
| 2024-11-08 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-11-08 | Needham | Upgrade | Buy | Buy |
Profile
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-08-11 | BARABE TIMOTHY CRAIG | Director | 21.77K | Purchase |
| 2024-10-10 | HOGE ELIZABETH | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
| 2024-11-19 | JEWELL CHRISTOPHER M | Officer | 39.94K | Conversion of Exercise of derivative security |
| 2024-10-10 | KALAYOGLU MURAT | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
| 2024-12-09 | KURTOGLU METIN | Chief Technology Officer | 51.03K | Conversion of Exercise of derivative security |
| 2024-06-30 | MALIK KEMAL | Director | 5.93K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | FMR, LLC | 2.85M | 55.18M | 11.22% |
| 2024-09-29 | MPM BioImpact Capital LLC | 629.42K | 12.18M | 2.48% |
| 2024-09-29 | Siren, L.L.C. | 572.24K | 11.07M | 2.25% |
| 2024-09-29 | Blackrock Inc. | 423.47K | 8.19M | 1.67% |
| 2024-09-29 | Citadel Advisors Llc | 375.77K | 7.27M | 1.48% |
| 2024-09-29 | JP Morgan Chase & Company | 309.02K | 5.98M | 1.22% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | Fidelity Select Portfolios - Biotechnology | 936.69K | 18.12M | 3.69% |
| 2024-10-30 | Fidelity Select Portfolios - Health Care | 368.99K | 7.14M | 1.45% |
| 2024-10-30 | Fidelity Growth Company Fund | 341.35K | 6.61M | 1.34% |
| 2024-10-30 | Fidelity Advisor Health Care Fund | 230.25K | 4.46M | 0.91% |
| 2024-10-30 | iShares Russell 2000 ETF | 177.73K | 3.44M | 0.70% |
| 2024-10-30 | Fidelity Advisor Biotechnology Fund | 167.95K | 3.25M | 0.66% |
Split
| Split | Date |
|---|---|
| 1 : 30 | 2024-04-05 |